Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2025 Feb 13;65(2):2402434.
doi: 10.1183/13993003.02434-2024. Print 2025 Feb.

Reply to: Response and remission in asthma with tezepelumab: overlapping concepts informing on type-2 inflammatory-dependent treatment effects

Neil Martin  1   2 , Michael E Wechsler  3 , Christopher E Brightling  4 ; all authors of “Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies”
Affiliations
Comment

Reply to: Response and remission in asthma with tezepelumab: overlapping concepts informing on type-2 inflammatory-dependent treatment effects

Neil Martin et al. Eur Respir J. .

Abstract

Achieving on-treatment clinical remission with tezepelumab was associated with high baseline inflammatory biomarkers, but those achieving remission were observed to have less severe disease at baseline than those who achieved complete clinical response https://bit.ly/3P0C52q

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: N. Martin is an employee of AstraZeneca and may own stock or stock options in AstraZeneca. M.E. Wechsler is an employee of National Jewish Health and has received consultancy fees from AstraZeneca, Equillium, Genentech, GSK, Novartis, Regeneron Pharmaceuticals, resTORbio, Sanofi and Teva Pharmaceuticals. C.E. Brightling has received grants and consultancy fees from 4D Pharma, AstraZeneca, Chiesi, Genentech, Global Access Diagnostics (formerly Mologic), GSK, Novartis, Regeneron Pharmaceuticals, Roche and Sanofi.

Comment on

References

    1. Wechsler ME, Brusselle G, Virchow JC, et al. . Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies. Eur Respir J 2024; 64: 2400316. doi:10.1183/13993003.00316-2024 - DOI - PMC - PubMed
    1. Hansen S, Søndergaard MB, von Bülow A, et al. . Clinical response and remission in patients with severe asthma treated with biologic therapies. Chest 2024; 165: 253–266. doi:10.1016/j.chest.2023.10.046 - DOI - PubMed
    1. Scelo G, Tran TN, Le TT, et al. . Exploring definitions and predictors of response to biologics for severe asthma. J Allergy Clin Immunol Pract 2024; 12: 2347–2361. doi:10.1016/j.jaip.2024.05.016 - DOI - PubMed
    1. Perez-de-Llano L, Scelo G, Tran TN, et al. . Exploring definitions and predictors of severe asthma clinical remission after biologic treatment in adults. Am J Respir Crit Care Med 2024; 210: 869–880. doi:10.1164/rccm.202311-2192OC - DOI - PMC - PubMed
    1. Shackleford A, Heaney LG, Redmond C, et al. . Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis. Lancet Respir Med 2025; 13: 23–34. doi:10.1016/S2213-2600(24)00293-5 - DOI - PubMed

LinkOut - more resources